Back to results
US 2011/0212970 A1Published application
Compounds that modulate intracellular calcium
AssigneeCalcimedica, Inc.
InventorsGONUL VELICELEBI, KENNETH A. STAUDERMAN, JEFFREY P. WHITTEN, YAZHONG PEI, JIANGUO CAO, ZHIJUN WANG, EVAN ROGERS, BRIAN DYCK, JONATHAN GREY
Life of this patent
Estimating the term…
Abstract
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
Claims26
A compound of Formula (I):
- wherein:
- A is phenyl or benzofuran, wherein phenyl and benzofuran are each optionally substituted with at least one R;
- or A is phenyl substituted with two R groups on adjacent carbon atoms wherein the two R groups and the carbon atoms to which they are attached form a C4-C8cycloalkyl or C3-C8heterocycloalkyl;
- R is selected from F, Cl, Br, I, —CN, —NO2, —CF3, —OH, —OR3, —OCF3, —C═CH, —C═CR3, C1-C6alkylenealkyne, C1-C6alkyl, C3-C6cycloalkyl, C1-C6heteroalkyl, C1-C6haloalkyl, tetrazolyl, C2-C6heterocycloalkyl, phenyl, —NHS(═O)2R3, S(═O)2N(R4)2, —C(═O)CF3, —C(═O)NHS(═O)2R3, —S(═O)2NHC(═O)R4, N(R4)2, —N(R4)C(═O)R3, —CO2R4, —C(═O)R3, —OC(═O)R3, —C(═O)N(R4)2, —SR3, —S(═O)R3, and —S(═O)2R3;
- J is a bond, NHS(═O)2, S(═O)2N(R4), —C(═O), —C(═O)NHS(═O)2, —S(═O)2NHC(═O), N(R4), —N(R4)C(═O), —CO2, —C(═O), —OC(═O), —C(═O)N(R4), —S, —S(═O), and —S(═O)2, C1-C6alkylene, C2-C6alkenylene, C2-C6alkynylene, C1-C6heteroalkylene, C3-C6cycloalkylene, or C2-C6heterocycloalkylene, wherein C1-C6alkylene, C2-C6alkenylene, C2-C6alkynylene, C1-C6heteroalkylene, C3-C6cycloalkylene, and C2-C6heterocycloalkylene is optionally substituted with at least one R;
- R1 is CO2R2 or a carboxylic acid bioisostere, wherein R2 is hydrogen, C1-C6alkyl, C1-C6cycloalkyl, C1-C6haloalkyl, phenyl or benzyl;
- Z is O, S, NH, N—CN, or CHNO2;
- X is W-L-phenyl, W-L-B, B, W-L-D, or D wherein phenyl, B, and D are each optionally substituted with at least one R;
- W is NR2, O or a bond;
- L is methylene, ethylene substituted with at least one R, C3-C6alkylene, C2-C6alkenylene, C2-C6alkynylene, C1-C6heteroalkylene, C3-C6cycloalkylene, or C2-C6heterocycloalkylene, wherein methylene, C3-C6alkylene, C2-C6alkenylene, C2-C6alkynylene, C1-C6heteroalkylene, C3-C6cycloalkylene, and C2-C6heterocycloalkylene is optionally substituted with at least one R;
- B is selected from furan, thiophene, pyrrole, pyridine, oxazole, thiazole, imidazole, thiadiazole, isoxazole, isothiazole, pyrazole, pyridazine, pyrimidine, pyrazine, oxadiazole, thiadiazole, triazole, indole, benzoxazole, benzothiazole, benzimidazole, benzoxadiazole, benzothiadiazole, benzotriazole, pyrazolopyridine, imidazopyridine, pyrrolopyridine, pyrrolopyrimidine, indolizine, purine, furopyridine, thienopyridine, furopyrrole, furofuran, thienofuran, 1,4-dihydropyrrolopyrrole, thienopyrrole, thienothiophene, quinoline, isoquinoline, furopyrazole, thienopyrazole, and 1,6-dihydropyrrolopyrazole;
- D is C3-C10cycloalkyl or C2-C9heterocycloalkyl;
- each R3 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, phenyl, and benzyl;
- each R4 is independently selected from hydrogen, C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, phenyl, and benzyl;
- or
- a pharmaceutically acceptable salt, solvate, N-oxide or prodrug thereof.
13 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.